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MicroRNAs (miRNAs) are a class of small, non-coding RNAs that are recognized as critical
regulators of immune gene expression during infection. Many immunologically significant
human miRNAs have been found to be conserved in agriculturally important species, includ-
ing cattle. Discovering how bovine miRNAs mediate the immune defense during infection
is critical to understanding the etiology of the most prevalent bovine diseases. Here, we
review current knowledge of miRNAs in the bovine genome, and discuss the advances
in understanding of miRNAs as regulators of immune cell function, and bovine immune
response activation, regulation, and resolution. Finally, we consider the future perspectives
on miRNAs in bovine viral disease, their role as potential biomarkers and in therapy.
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INTRODUCTION
MicroRNAs (miRNAs) are short, non-coding RNAs, which post-
transcriptionally regulate gene expression (1). Since their initial
discovery in 1993 (2), studies have convincingly demonstrated crit-
ical roles for miRNAs in the regulation of many cellular processes,
such as differentiation and proliferation (3). There is also substan-
tial evidence, primarily from human and mouse studies, which
miRNAs regulate innate and adaptive immune mechanisms (4,
5). However, the regulatory potential of miRNAs in agriculturally
important species, such as cattle, is poorly explored. Here, we aim
to review the role of miRNAs in bovine immune and inflammatory
systems.
MicroRNA BIOGENESIS
MicroRNAs are transcribed by RNA Polymerase II or III as
primary miRNAs (pri-miRNAs) in the nucleus, and are then
processed into pre-miRNAs by the Microprocessor multiprotein
complex, and the co-factor DiGeorge Syndrome Critical Region
8 (DGCR8/Pasha) (6). Following export to the cytoplasm by
exportin 5 (XPO5), a mature 22 nucleotide long duplex is formed
by an RNAse type III enzyme, called Dicer (7). The duplex,
together with Trans-Activation Responsive RNA-Binding Protein
2 (TARBP2) and Argonaute (AGO) family proteins, form a com-
plex, which triggers the assembly of the RNA-Induced Silencing
Complex (RISC). One miRNA strand is removed, and the other
strand guides RISC to its target mRNA via base-pairing (6). The
recognition of the target binding site, which can be found in the
coding or the untranslated regions (UTR) of the mRNA, mostly
depends on a part called the seed sequence (nucleotides 2–7 at the
5′ end) of the miRNA (7). Although both strands of the duplex
can be functional, usually only one strand is used (8).
MicroRNAs are evolutionarily conserved and have been found
in all eukaryotes from unicellular species to mammals (9). To date,
2588 have been identified in the human genome, 1915 in mouse,
and 793 in bovine (miRBase version 21, http://www.mirbase.org)
(10). Originally, miRNAs were thought to mainly regulate gene
expression by inhibiting translation, however, transcriptional reg-
ulation has been shown recently to be the primary mechanism used
by miRNAs to influence gene expression in mammals (11). Several
important factors determine how miRNAs function, including the
location and number of target sites within mRNA 3′ UTRs (or
other gene regions), RNA-binding proteins (RBPs), which inter-
fere with RISC binding, RISC co-factors, and the modification of
RISC-components (12). Transcripts with target sites for a common
miRNA compete for recognition. These competing endogenous
RNAs (ceRNA), such as other mRNAs, long non-coding RNAs
(lncRNA), pseudogene transcripts, and independently transcribed
UTRs, can reduce the effect of specific miRNAs in vivo. Binding to
target sites also protects miRNAs from degradation, in a process
called target mediated miRNA protection (TMMP) (12). Indi-
vidual miRNAs can have many targets, explaining how relatively
small numbers of alternatively expressed miRNAs can have a large
impact on gene regulation and control several diverse biological
processes.
MicroRNAs IN IMMUNITY AND INFECTION
Cell-type specific expression of miRNAs has been demonstrated in
innate and adaptive immune cells (13, 14) and there is a growing
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body of evidence that miRNAs regulate the differentiation, devel-
opment, and function of these cells (15–17). Hematopoietic stem
cell differentiation into myeloid and lymphoid lineages, for exam-
ple, has been shown to be under the influence of several miRNAs,
including miR-125b, miR-126, and miR-196b (4, 18). Addition-
ally, the deletion of the dicer1 gene, which is critical for proper
miRNA processing, results in impaired T cell development (19),
while miR-17–92, miR-150, and miR-155 have been demonstrated
to be critical for B cell development. Other roles for miRNAs in
regulating adaptive immunity have also been shown, including the
regulation of B and T lymphocyte functions, including antibody
production, by miR-155 (20–22). Activation of the innate immune
system is also regulated by miRNAs (23). The human miRNA,
miR-146a, for example, has been shown to target tumor necro-
sis factor receptor-associated factor 6 (TRAF6) and interleukin-1
(IL1) receptor-associated kinase (IRAK1), key regulatory nodes,
which control innate immune signaling in response to lipopolysac-
charide (LPS) (24). Similarly, miR-19a has been shown to regu-
late expression of SOCS 3, an important suppressor of cytokine
signaling (25).
MicroRNAs have also been clearly demonstrated to have impor-
tant roles in regulating responses to infection (26). In particular,
several miRNAs have been identified to have important functions
in regulating immune responses to mycobacterial infection (27).
Tumor necrosis factor (TNF) biosynthesis, for example, is inhib-
ited by Mycobacterium tuberculosis – an intracellular mycobacterial
pathogen that infects alveolar macrophages – by altering levels of
human macrophage miRNAs, including miR-125b and miR-155,
for its own benefit (28). Similarly, miR-29 and miR-99b regulate
the production of multiple cytokines, including IFN-γ and TNF-α,
which control M. tuberculosis growth (29, 30). miRNAs are fre-
quently evolutionarily conserved and many of these miRNAs have
orthologs in cattle, therefore data from human and mouse studies
can provide a roadmap for revealing miRNAs likely to have impor-
tant roles in bovine infectious diseases. Many miRNAs, however,
exhibit pathogen or stimulus-specific response profiles and cer-
tain families of miRNAs are expanded or contracted in the bovine
genome.
MicroRNAs IN THE BOVINE GENOME
The first studies demonstrating miRNA expression in bovine tis-
sues were undertaken in 2007 (31, 32). Since then, 793 mature
miRNAs, encoded on all 30 chromosomes, have been identified
in the Bos taurus genome. These miRNAs account for approx-
imately a quarter of all the 3825 non-coding RNAs predicted
in the genome by Ensembl (v75) (33). Typically, miRNAs have
been grouped into families based on shared sequence similar-
ity of the miRNA seed region (2–8 nt), the mature sequence,
or the precursor miRNA sequence (34). Often, miRNA fami-
lies can be found clustered with target genes in specific genomic
regions (35). Many human miRNAs, including some of the most
extensively studied immune-related miRNAs, share significant
functional and sequence similarities to their bovine counterparts
indicating evolutionary conservation and, putatively, conserva-
tion of function. The human miRNA, hsa-miR-155, for example,
is a perfect homolog to its bovine counterpart bta-miR-155. In
humans, this miRNA acts as an anti-inflammatory agent targeting
the Toll-like receptor/Interleukin-1 receptor (TLR/IL1R) inflam-
matory pathway (36). Another miRNA with a conserved bovine
ortholog, hsa-miR-146a-5p, is known to negatively regulate the
retinoic acid-inducible gene 1 (RIG-I) pathway in humans by
suppressing TRAF6 and IRAK1 during viral infection (37). There
is also an exact seed sequence match between hsa-miR-146a-5p,
bta-miR-146a, and mmu-miR-146a-5p.
While there is significant conservation of miRNAs between
species, there are also notable differences that very likely have
functional consequences. There are numerous cases, for exam-
ple, of miRNAs found in the human genome that are apparently
absent in bovine. Some of these differences may be due to bet-
ter annotation of the human microRNAome but clearly there are
real differences too. The human miRNA, hsa-miR-198, for exam-
ple, has a role in human immunity and has no apparent homolog
in the bovine genome. This miRNA targets the Cyclin T1 gene
(CCNT1), which acts as a co-factor for HIV-1 (38).
In addition to single miRNA differences in the repertoire of
human and bovine miRNAs, there are also several cases where
entire families or clusters of miRNAs that are present in human
have yet to be discovered or do not exist in the bovine genome.
These include the majority of miRNAs numbered from miR-550 to
miR-640; some 200 miRNAs, which include the hsa-miR-515 clus-
ter (11 miRNAs), and interestingly, the miR-548 family. The miR-
548 family comprises of over 70 miRNAs whose expression to date
has only been described in simians. Members of this miRNA fam-
ily have been shown to target interferon-λ1 (IFN-λ1), modulating
the primate interferon response to viral infections (39).
There are also several miRNA families in the bovine genome
that are apparently species-specific, at least when compared to
available genomes. The bta-miR-2284 and bta-miR-2285 families,
for example, encode more than 100 mature miRNAs in the bovine
genome but do not appear to have homologs in either human or
mouse. These miRNA families have been shown to be expressed
in a number of bovine immune-relevant tissues including CD14+
monocytes, mammary epithelial cells, and alveolar macrophages
(40–42), however, the genes targeted by the miRNAs in this family
are currently unknown.
ROLE OF THE miRNAs IN THE BOVINE IMMUNE SYSTEM
The roles that miRNAs play in regulating immune activation
and resolution in response to infection is less well understood
in cattle, compared to human and mouse. Investigations in cattle
have primarily focused on characterizing miRNA expression in
immune-related tissues and investigating whether miRNA expres-
sion is perturbed during bacterial/viral infections – but detailed
mechanistic studies are, to date, largely lacking. One of the first
studies to profile immune-relevant miRNA expression in cattle,
characterized the expression of more than 100 bovine orthologs
of known human miRNAs, as well as novel bovine miRNAs, in
several immune-relevant tissues and provided an early bovine
miRNA expression atlas for many later studies (31). More recently,
Vegh et al. utilized a next generation sequencing (NGS) strategy
to profile miRNA expression on a genome-wide scale in bovine
alveolar macrophages, the primary host cell for M. bovis, an
economically important pathogen (41). NGS has several advan-
tages over classical sequencing technologies, which include the
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ability to accurately measure expression of all miRNAs simultane-
ously, with high reliability, single-nucleotide resolution and across
the broad dynamic range of expression (43). miRNA expression
has now been demonstrated in 10 immune-related bovine tis-
sues (bovine embryo, thymus, small intestine, mesenteric lymph
node, abomasum lymph node, CD14+ blood isolated monocytes,
CD14+ milk-isolated monocytes (MIMs), mammary epithelial
cells, alveolar macrophages, mammary tissue, and in the MDBK
cell line) and tissue-specific expression of miRNAs in these tissues
is readily apparent (Figure 1) (31, 40–42, 44–47).
Several studies have also examined whether miRNA expres-
sion is altered in response to Gram-positive or Gram-negative
infections associated with bovine mastitis, a disease of the bovine
mammary gland with significant economic consequences to the
dairy industry. Naeem et al. examined a panel of 14 miR-
NAs from mammary tissue biopsied during an in vivo intra-
mammary Streptococcus uberis infection (46). Four of the four-
teen miRNAs were found to undergo differential expression
(Table 1). Another study compared transcriptional changes of five
inflammation-associated miRNAs, including ones with extensively
studied human orthologs: bta-miR-155, bta-miR-146a, and bta-
miR-223, in bovine CD14+ monocytes stimulated with either LPS
or Staphylococcus aureus enterotoxin B (SEB) (45). Four miRNAs
were differentially expressed, and LPS was found to have a greater
effect than SEB at inducing miRNA differential expression.
More recent studies have employed high-throughput sequenc-
ing approaches to temporally profile genome-wide changes in
miRNA expression in different cell-types in response to challenge
with bovine mastitis-causing pathogens such as Escherichia coli, S.
aureus, and S. uberis. Lawless et al. identified 21 miRNAs that were
differentially expressed in bovine mammary epithelial (BMEs)
cells challenged in vitro with live S. uberis, a Gram-positive bac-
terium (40). Strikingly, the 21 miRNAs differentially expressed in
response to this Gram-positive bacterium was substantially differ-
ent to LPS-responsive miRNAs. Furthermore, the predicted target
genes of miRNAs that were down-regulated in BMEs following
S. uberis infection (but not the targets of up-regulated miRNAs),
were statistically enriched for roles in innate immunity, suggest-
ing that the repression of these miRNAs transcriptionally releases
the innate immune response to this infection. Subsequently, Jin
et al. also reported notable differences in miRNA expression pro-
files in MAC-T cells challenged with either heat-killed E. coli
or S. aureus (47). This was the first bovine study to directly
FIGURE 1 | Multidimensional scaling (MDS) plot of miRNA profiles
shows that miRNA expression is cell-type specific. Similar cell-types
have similar profiles, as evidenced by milk (+) and blood CD14+ cells (o),
and by bovine mammary epithelial cells [primary (*) and cell line (M)], which
group together. Data are from four recent RNA-seq publications. +, Blood
CD14+ monocytes; o, milk CD14+ monocytes; ×, bovine alveolar
macrophage; *, primary bovine mammary epithelial cells (BME); M, bovine
mammary epithelial cell line (MAC-T).
Table 1 | Summary of bovine miRNA literature.
Reference miRNA Tissue Source Condition
(31) Genome-wide embryo, thymus, lymph node, and
small intestine
Holstein–Friesian None
(44) Genome-wide Bos taurus kidney cells (MDBK) Cell line Bovine herpesvirus 1
(46) miR-10a, -15b, 16a, -17, -21, 31, -145, 146a,
146b, 155, -181a, -205, -221, and -223
Mammary tissue Holstein–Friesian Mastitis
(48) miR-223 Venous blood Holstein–Friesian Mastitis
(45) miR-9, -125b, -155, -146a, and -223 CD14 monocytes ex vivo Holstein–Friesian LPS and SEB
(49) miR-296, -2430, -671, and -2318 Mammary tissue Holstein–Friesian Mastitis
(39) miR-17-5p, -20b, and -93 Mammary tissue Holstein–Friesian Mastitis
(40) Genome-wide Mammary epithelial cells ex vivo Holstein–Friesian Mastitis
(41) Genome-wide Alveolar macrophages Holstein–Friesian None
(39) Genome-wide Peripheral blood Holstein–Friesian Mastitis
(42) Genome-wide CD14 monocytes Holstein–Friesian Mastitis
(47) Genome-wide MAC-T cells Cell line Heat-inactivated E. coli or
S. aureus
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compare global miRNA expression of two pathogens in the same
cell-type.
In the first NGS-based study to temporally profile infection-
induced miRNA responses in vivo, Lawless et al. simultaneously
profiled genome-wide mRNA and miRNA expression at multi-
ple time-points in both milk and blood FACS-isolated CD14+
monocytes from cattle infected with S. uberis (42). Twenty-six
miRNAs and more than 3500 genes were identified as being
significantly differentially expressed over the 48 h time-course.
In MIMs, up-regulated protein-coding genes were significantly
enriched for inflammatory and innate immune pathways, while
down-regulated genes were enriched for non-glycolytic metabolic
pathways. Monocyte transcriptional changes in the blood were
more subtle. Pathway analysis revealed that predicted targets of
MIM down-regulated miRNAs were highly enriched for roles in
innate immunity, while up-regulated miRNAs preferentially tar-
geted genes involved in metabolism; suggesting that during S.
uberis infection miRNAs are key amplifiers of monocyte inflam-
matory response networks and repressors of several metabolic
pathways.
To date, only one study has examined whether bovine miR-
NAs are transcriptionally perturbed during viral infection. In this
study, an adult bovine kidney cell line was challenged with bovine
herpes virus 1. Sequencing 3 miRNA libraries, more than 300 miR-
NAs were found to expressed, but none were described as being
differentially expressed (44).
VALIDATED BOVINE miRNA TARGET GENES
Two approaches are commonly used to validate miRNA targets.
One involves transfection of miRNA mimics (or inhibitors) into
cells and confirmation that the expression of predicted target
genes is altered as expected (50). This approach provides evi-
dence that a given miRNA can alter the expression of a target gene
but does not prove direct regulation (51). The miRNA could, for
example, regulate a transcription factor, which subsequently reg-
ulates the putative target gene. A more direct approach is to use a
reporter assay, where the 3′ UTR of the predicted target gene (or at
least the portion containing the predicted miRNA binding site) is
cloned upstream of a luciferase or green fluorescent protein (GFP)
reporter gene. If binding of the transfected miRNA mimic to the
3′ UTR reduces the level of reporter protein this demonstrates a
direct silencing effect of the miRNA on the gene (52).
To date, very few studies have functionally validated bovine
miRNA targets. One example where miRNA regulation has been
validated is bovine High Mobility Group Box 1 (HMGB1), a
nuclear protein, which transcriptionally regulates inflammation
(48). Bovine HMGB1 has been shown to be targeted by bta-miR-
223, a miRNA that is up-regulated during S. aureus infection (48).
Similarly, using reporter assays, bta-miR-124 has been shown to
regulate expression of Monocyte Chemotactic Protein 1 (MCP1)
and Polypyrimidine Tract Binding Protein 1 (PTBP1) in bovine
fibroblasts (53).
OTHER AREAS OF BOVINE miRNA IMMUNE BIOLOGY
In addition to their role as intracellular transcriptional modu-
lators of gene expression miRNAs are also stably expressed in a
host of extracellular body fluids including milk, saliva, semen, and
plasma (54–57). Extracellular miRNAs can be transferred to dis-
tant recipient cells via exosome-mediated transfer and have been
demonstrated, in mouse dendritic cells, to modulate recipient cell
transcription (58). Exosome packaged miRNAs have been shown
to be highly stable and are resistant to degradation by RNases,
freeze-thaw, and low pH (56, 59). Exosome miRNAs – includ-
ing a number of immune-relevant ones, such as bta-miR-223 and
bta-miR-125b – have been found in both human breast milk and
bovine milk (54–56). MicroRNA expression levels in milk have also
been observed to vary during different lactation periods and are
present in milk products as well as in raw milk (54). Interestingly,
they are particularly abundant in colostrum. Further investiga-
tion of the role of exosome packaged miRNAs play in regulating
mammalian immunity is urgently needed.
FUTURE RESEARCH DIRECTIONS IN BOVINE miRNAs AND
THEIR EFFECT ON IMMUNOLOGY, INFLAMMATION, AND
INFECTION
It is clear that miRNAs play a key role in regulating human and
mouse immune responses. In cattle, studies to date have been
mainly limited to demonstrating differential expression of miR-
NAs in immune-relevant tissues or cells challenged in vitro with
specific pathogens. Importantly, annotated miRNAs are much
fewer in the bovine genome than in murine or human genomes,
and a bovine miRNA expression atlas across bovine tissues and
cells is needed to bridge this gap. Among its many uses, better
annotation of non-coding RNAs would aid in the interpretation of
bovine genome-wide association study (GWAS) data. A previously
unannotated small non-coding RNA, for example, was recently
identified as the only gene in a novel genome-wide significant
QTL for somatic cell score, a mastitis indicator trait (60).
Aside from understanding the important basic biology of how
miRNAs regulate bovine gene expression, miRNAs could also
potentially be of significant utility as biomarkers of specific dis-
eases in cattle. Indeed, miRNAs exhibit many properties that have
made them of significant interest as non-invasive biomarkers in
human clinical studies. miRNAs are abundantly expressed, in a
stable form, in a range of extracellular fluids, are easily measured,
and in many cases exhibit temporal and spatial specificity (54–
57). They also have high information content – small numbers
of miRNAs can serve as accurate biomarkers. Several studies have
investigated miRNA expression profiles associated with different
mastitis-causing pathogens (Table 1), however, many of these
studies were carried out in vitro, and the potential of miRNAs
as biomarkers of bovine disease is currently limited by a lack
of studies of in vivo comparison of miRNA profiles associated
with multiple different pathogens in the same challenge model.
Such in vivo studies are needed to identify sensitive and specific
biomarkers for particular infections. This could be used for identi-
fying infections, such as tuberculosis, using a simple miRNA-based
biomarker, or for distinguishing between different infections, for
example between E. coli and S. uberis driven mastitis, helping
veterinarians to select more specific therapeutic strategies.
A further limitation is the fact that research investigating the
role of miRNAs in regulating bovine immunity has, to date,
focused almost exclusively on bacterial infections and little is
known about the role miRNAs play during bovine viral infections.
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Some of the most economically important and high profile bovine
infectious diseases are of viral origin including Foot and Mouth
Disease Virus (FMDV) (61), Bovine Viral Diarrheal Virus (BVDV)
(62), and the recently described Schmallenberg virus (63). In other
species, it is clear that host miRNAs have a direct role in modu-
lating the host immune response to pathogenic viral infections
(38). Additionally, some viruses encode their own repertoire of
miRNAs to subvert the host immune response. Nearly 200 viral
miRNAs have been described (64). Describing their precise effect
on the immune response could further our understanding of both
bovine miRNA immune biology and virology.
Aside from their utility as biomarkers, miRNAs also have sig-
nificant potential as therapeutic targets or agents. MicroRNA
function can be augmented either by over-expression approaches,
using miRNA mimics or vector based over-expression, or by inhi-
bition,using miRNA sponges or anti-miR oligonucleotides (65). In
humans, several miRNAs are currently in preclinical and clinical
trials as novel therapeutics in cancer, viral infections, and car-
diovascular disease (65). Human miR-122, for example, is being
investigated for its therapeutic potential to modulate cholesterol
metabolism (66). Additionally, targeting miR-122 using the anti-
miR miravirsen induces antiviral activity against hepatitis C virus
(HCV) (67). The potential clinical utility of miR-122 is being
investigated in Phase II clinical trials. Similarly, human miR-208
has been shown to have an important role in modulating cardiac
function and remodeling (68), and is currently in preclinical trials.
Interestingly from a bovine perspective, this miRNA also has a big
impact on metabolism. Treatment with anti-miR-208 prevented
weight gain in aging mice, which was due to a reduction in fat
weight (69).
All of the miRNAs mentioned above with therapeutic potential
have orthologs in cattle and these examples clearly suggest that
there is a potential for the application of miRNA-based therapeu-
tic strategies to combat disease and regulate metabolism in cattle
in order to influence important economic traits, such as growth,
feed efficiency, or milk production. Although the cost of miRNA
therapy and the large size of animals may prevent agricultural use,
bovine research models still could be valuable, as the conserved
nature of miRNAs facilitates translation of research to human
application (65).
A current limitation to the translational potential of miRNA
biology in cattle is the lack of validated targets for known miRNAs,
as only a handful of studies to date have functionally validated
predicted miRNA targets (40, 41). Computationally, hundreds
if not thousands of putative miRNA targets can be predicted
and experimental validation is a costly and labor-intensive pro-
cedure. Methods which integrate and correlate miRNA expression
with mRNA expression in the same sample can refine computa-
tional predictions and increase the validation hit rate. Other more
recent technological advancements such as crosslinking immune-
precipitation sequencing (CLIP-Seq) can directly identify miRNA
targets on a genome-wide scale (70), but such approaches have yet
to be implemented in cattle.
In conclusion, miRNAs undoubtedly play a key role in reg-
ulating bovine immunity and disease. Future studies are poised
to reveal their true potential as novel biomarkers or therapeutic
agents in a range of bovine diseases as well as providing further
insight into the fundamental biology of how they regulate bovine
immune gene expression, insight which is essential before their
translational potential can be realized fully.
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